Skip to main content

Table 2 Studies of IO in combination with CRT in inoperable stage III NSCLC

From: Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy

Trial

NCT

Study phase

Number of patients

Status

Trial design

RT details

Median FU (mos)

Median PFS (mos)

Median OS (mos)

PACIFIC [85]

NCT02125461

IIIR

713/709 received consolidation

Active, not recruiting

cCRT→durvalumab vs. placebo

54–66 Gy

25.2

17.2

NR

PACIFIC-2 [86]

NCT03519971

IIIR

300

Active, not recruiting

cCRT + durvalumab→durvalumab vs. cCRT + placebo→placebo

60 Gy

X

X

X

PACIFIC-5 [87]

NCT03706690

IIIR

360

Recruiting

cCRT→durvalumab fixed dose vs. cCRT→placebo

54–66 Gy

X

X

X

PACIFIC-6

NCT03693300

II

150

Recruiting

sCRT→durvalumab

54–66 Gy

X

X

X

COAST [88]

NCT03822351

IIR

300

Recruiting

cCRT→durvalumab vs. cCRT→durvalumab + Oleclumab vs. cCRT→durvalumab + monalizumab

54–66 Gy

X

X

X

DETERRED-PART I [89, 90]

NCT02525757

II

10

Active, not recruiting

cCRT→CT + atezolizumab→atezolizumab

60–66 Gy

22.5

18.6

22.8

DETERRED-PART II [89, 90]

NCT02525757

II

30

Active, not recruiting

cCRT + atezolizumab→CT + atezolizumab→atezolizumab

60–66 Gy

15.1

13.2

NR

NICOLAS [91]

NCT02434081

II

82/94 per protocol v2.0/v3.0

Active, not recruiting

3x CT → RT + nivolumab→nivolumab (sCRT arm of v2.0) OR 1x CT → cCRT + nivolumab→nivolumab

66 Gy

13.4

X

X

HCRN LUN 14–179 [92, 93]

NCT02343952

II

92

Active, not recruiting

cCRT→pembrolizumab

59–66.6 Gy

16.4

15.4

NR

Rutgers [94]

NCT02621398

I

21/23 evaluable

Active, not recruiting

cCRT→pembrolizumab (cohort 1: 4 pts) & cCRT + pembrolizumab→pembrolizumab (cohorts 2–6: 19 pts)

60 Gy

16

18.7

29.4

CLOVER NSCLC

NCT03509012

I

300 solid tumors (NSCLC, HNSCC, SCLC)

Recruiting

cCRT + durvalumab

X

X

X

X

KEYNOTE-799

NCT03631784

II

216

Recruiting

1x CT + pembrolizumab→cCRT + pembrolizumab→pembrolizumab

60 Gy

X

X

X

H. Lee Moffitt Cancer Center

NCT03663166

I/II

50

Recruiting

cCRT +2x ipilimumab→nivolumab

60 Gy

X

X

X

Alliance Foundation

NCT03102242

II

64

Active, not recruiting

2x OR 4x atezolizumab→cCRT→2x CT → atezolizumab

60 Gy

X

X

X

EMD Serono

NCT03840902

IIR

350

Recruiting

cCRT + M7824 → M7824 vs. cCRT + placebo→durvalumab

60 Gy

X

X

X

CheckMate73L

NCT04026412

IIIR

1400

Recruiting

cCRT + nivolumab →nivolumab + ipilimumab OR cCRT + nivolumab→nivolumab vs. cCRT→durvalumab

X

X

X

X

CONSIST

NCT03884192

IIIR

162

Recruiting

cCRT→sintilimab (IBI308) vs. cCRT alone

X

X

X

X

CStone Pharmaceuticals

NCT03728556

IIIR

702

Recruiting

sCRT/cCRT→CS1001 mAb vs. placebo

X

X

X

X

Sun Yat-sen University

NCT04085250

IIR

264

Recruiting

CT + nivolumab→cCRT→nivolumab vs. observation

X

X

X

X

NCI study

NCT04092283

IIIR

660

Recruiting

cCRT + durvalumab→durvalumab vs. cCRT→durvalumab

X

X

X

X

BTCRC-LUN16–081

NCT03285321

IIR

108

Recruiting

cCRT→nivolumab vs. nivolumab + ipilimumab

X

X

X

X

  1. Legend: c - concurrent; CT - chemotherapy; s - sequential; CRT - chemoradiotherapy; R - randomised; Gy - Gray; PFS - progression-free survival; OS - overall survival; NR - not reached; X - not available; FU - follow-up; HNSCC - squamous cell carcinoma of the head and neck (HNSCC); mAb - monoclonal antibody; NSCLC - Non-small cell lung cancer; SCLC - Small cell lung cancer
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us